Neuropeptides: Animal Behaviour and Human Psychopathology

Overview

Journal Eur Arch Psychiatry Neurol Sci

Specialties Neurology
Psychiatry

Date 1989 Jan 1

PMID 2670577

Citations 1

Authors

D de Wied

J M van Ree

Affiliations

Soon will be listed here.

Abstract

Animal studies have demonstrated that neuropeptides modulate nervous system functions. It has been postulated that disturbances in neuropeptide systems may be aetiological factors in psychiatric and neurological disorders. Neuropeptides related to ACTH/MSH, including ORG 2766, increase motivation and attention and facilitate recovery processes after nerve damage. These peptides may be effective during the early stage of dementia. Vasopressin and related peptides improve memory processes in animals and humans. In addition, these peptides influence social behaviour, mood and addictive behaviour. The non-opioid gamma-type endorphins have neuroleptic-like activities in animals and antipsychotic effects in a category of schizophrenic patients. Peptides related to CCK have also been found to be effective in these patients. Some neuropeptides, e.g. TRH and PLG, have been reported to exert antidepressant effects. Further research may eventually produce neuropeptides with therapeutic action in psychiatric and neurological diseases.

Citing Articles

Cerebrospinal fluid levels of hypothalamic-pituitary-adrenal axis hormones in MCI and dementia due to Alzheimer's disease: a systematic review.

Duarte-Zambrano F, Barrero J, Mockus I Dement Neuropsychol. 2023; 17:e20230031.

PMID: 38089172 PMC: 10715237. DOI: 10.1590/1980-5764-DN-2023-0031.

References

Tamminga C, Tighe P, Chase T, DeFraites E, SCHAFFER M . Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report. Arch Gen Psychiatry. 1981; 38(2):167-8. DOI: 10.1001/archpsyc.1981.01780270053006. View

van Ree J, Verhoeven W, de Wied D, van Praag H . The use of the synthetic peptides gamma-type endorphins in mentally ill patients. Ann N Y Acad Sci. 1982; 398:478-95. DOI: 10.1111/j.1749-6632.1982.tb39519.x. View

Bovenberg R, Burbach J, Wiegant V, Veeneman G, VAN Boom J, Baas P . gamma-Endorphin and schizophrenia: amino acid composition of gamma-endorphin and nucleotide sequence of gamma-endorphin cDNA from pituitary glands of schizophrenic patients. Brain Res. 1986; 376(1):29-37. DOI: 10.1016/0006-8993(86)90896-6. View

Itoh H, Tanoue S, Yagi G, Tateyama M, Kamisada M, Fujii Y . Clinical study on the psychotropic effects of caerulein--an open clinical trial in chronic schizophrenic patients. Keio J Med. 1982; 31(3):71-95. DOI: 10.2302/kjm.31.71. View

Davis T, Schoemaker H, Culling A . Centrally acting drugs alter in vitro beta-endorphin processing in the rat. Eur J Pharmacol. 1984; 100(2):249-51. DOI: 10.1016/0014-2999(84)90234-6. View

Reichlin S . Neural functions of TRH. Acta Endocrinol Suppl (Copenh). 1986; 276:21-33. DOI: 10.1530/acta.0.111s0021. View

Hammonds Jr R, Nicolas P, Li C . beta-endorphin-(1-27) is an antagonist of beta-endorphin analgesia. Proc Natl Acad Sci U S A. 1984; 81(5):1389-90. PMC: 344839. DOI: 10.1073/pnas.81.5.1389. View

MOROJI T, Watanabe N, Aoki N, Itoh S . Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide, on schizophrenia. Int Pharmacopsychiatry. 1982; 17(4):255-73. DOI: 10.1159/000468582. View

Nair N, Lal S, Bloom D . Cholecystokinin and schizophrenia. Prog Brain Res. 1986; 65:237-58. DOI: 10.1016/S0079-6123(08)60654-8. View

10.

Meltzer H, Busch D, TRICOU B, Robertson A . Effect of (Des-Tyr)-gamma-endorphin in schizophrenia. Psychiatry Res. 1982; 6(3):313-26. DOI: 10.1016/0165-1781(82)90021-x. View

11.

de Wied D, Jolles J . Neuropeptides derived from pro-opiocortin: behavioral, physiological, and neurochemical effects. Physiol Rev. 1982; 62(3):976-1059. DOI: 10.1152/physrev.1982.62.3.976. View

12.

Nemeroff C, Kalivas P, Golden R, Prange Jr A . Behavioral effects of hypothalamic hypophysiotropic hormones, neurotensin, substance P and other neuropeptides. Pharmacol Ther. 1984; 24(1):1-56. DOI: 10.1016/0163-7258(84)90027-5. View

13.

Nebes R, Reynolds 3rd C, Horn L . The effect of vasopressin on memory in the healthy elderly. Psychiatry Res. 1984; 11(1):49-59. DOI: 10.1016/0165-1781(84)90107-0. View

14.

Moss R, Foreman M . Potentiation of lordosis behavior by intrahypothalamic infusion of synthetic luteinizing hormone-releasing hormone. Neuroendocrinology. 1976; 20(2):176-81. DOI: 10.1159/000122481. View

15.

Casey D, Korsgaard S, Gerlach J, Jorgensen A, SIMMELSGAARD H . Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia. Arch Gen Psychiatry. 1981; 38(2):158-60. DOI: 10.1001/archpsyc.1981.01780270044005. View

16.

Niesink R, van Ree J . Normalizing effect of an adrenocorticotropic hormone (4-9) analog ORG 2766 on disturbed social behavior in rats. Science. 1983; 221(4614):960-2. DOI: 10.1126/science.6308767. View

17.

Nawa H, Kotani H, Nakanishi S . Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing. Nature. 1984; 312(5996):729-34. DOI: 10.1038/312729a0. View

18.

Bourgeois M, Laforge E, Muyard J, Blayac J, Lemoine J . [Endorphins and schizophrenias. II. Trial treatment of schizophrenia with des-Tyr-gamma-endorphin (DT gamma E) (including a personal trial)]. Ann Med Psychol (Paris). 1980; 138(9):1112-9. View

19.

Veldhuis H, de Wied D . Differential behavioral actions of corticotropin-releasing factor (CRF). Pharmacol Biochem Behav. 1984; 21(5):707-13. DOI: 10.1016/s0091-3057(84)80007-6. View

20.

Rosenfeld M, Mermod J, Amara S, Swanson L, Sawchenko P, Rivier J . Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 1983; 304(5922):129-35. DOI: 10.1038/304129a0. View